trial · primary record
Glofitamab
B Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2027-07-31 |
| Primary endpoint | Safety and adverse events (AEs) |
| Registry ID | NCT06213311 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:41.200Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06213311
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Glofitamab · compound